[go: up one dir, main page]

BG62068B2 - Хирудинмутеини и техни полиалкиленгликолови конюгати - Google Patents

Хирудинмутеини и техни полиалкиленгликолови конюгати Download PDF

Info

Publication number
BG62068B2
BG62068B2 BG098604A BG9860494A BG62068B2 BG 62068 B2 BG62068 B2 BG 62068B2 BG 098604 A BG098604 A BG 098604A BG 9860494 A BG9860494 A BG 9860494A BG 62068 B2 BG62068 B2 BG 62068B2
Authority
BG
Bulgaria
Prior art keywords
glu
gly
asn
hirudin
thr
Prior art date
Application number
BG098604A
Other languages
Bulgarian (bg)
English (en)
Inventor
Manfred Kurfuerst
Klaus Ruebsamen
Bernhard Schmied
Wolfgang Koerwer
Juergen Schweden
Hans Hoeffken
Original Assignee
Abbott Gmbh & Co.Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6394620&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BG62068(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Gmbh & Co.Kg filed Critical Abbott Gmbh & Co.Kg
Publication of BG62068B2 publication Critical patent/BG62068B2/bg

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81Protease inhibitors
    • C07K14/815Protease inhibitors from leeches, e.g. hirudin, eglin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/855Proteins from animals other than mammals or birds
    • Y10S530/858Proteins from animals other than mammals or birds insects; venom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Polyethers (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
BG098604A 1989-12-01 1994-02-28 Хирудинмутеини и техни полиалкиленгликолови конюгати BG62068B2 (bg)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3939800 1989-12-01

Publications (1)

Publication Number Publication Date
BG62068B2 true BG62068B2 (bg) 1999-01-29

Family

ID=6394620

Family Applications (1)

Application Number Title Priority Date Filing Date
BG098604A BG62068B2 (bg) 1989-12-01 1994-02-28 Хирудинмутеини и техни полиалкиленгликолови конюгати

Country Status (9)

Country Link
US (1) US5663141A (fr)
EP (1) EP0502962B1 (fr)
JP (1) JP3187044B2 (fr)
AT (1) ATE135374T1 (fr)
BG (1) BG62068B2 (fr)
CA (1) CA2067224C (fr)
DE (1) DE59010205D1 (fr)
ES (1) ES2084149T3 (fr)
WO (1) WO1991008229A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
DE4117784A1 (de) * 1991-05-31 1992-12-03 Basf Ag Herstellung von protein-polyalkylenglykolkonjugaten
FR2687681B1 (fr) * 1992-02-20 1995-10-13 Transgene Sa Conjugues polyethyleneglycol-hirudine, leur procede de preparation et leur emploi pour le traitement des thromboses.
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
CA2144523A1 (fr) * 1993-08-04 1995-02-16 Hugo Grossenbacher Desulfatohirudine de masse moleculaire elevee
DE4437502A1 (de) * 1993-12-02 1995-06-08 Basf Ag Hirudin-Konjugate aus Hirudin und lipophilen Verbindungen
DE4404168A1 (de) * 1994-02-10 1995-08-17 Hoechst Ag Hirudinderivate und Verfahren zu deren Herstellung
DE19533817C2 (de) * 1995-09-13 1999-12-09 Max Planck Gesellschaft Komplex-gebundene Hemmstoffe aktivierbarer Stoffwechselenzyme als molekulare Marker zur Diagnostik und Therapieüberwachung
US20040228852A1 (en) * 1999-04-08 2004-11-18 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V Use of increased molecular-weight hirudin as an anticoagulant in extracorporeal kidney replace therapy
DE19915862A1 (de) * 1999-04-08 2000-10-12 Max Planck Gesellschaft Verwendung von molekulargewichtserweitertem Hirudin als Antikoagulans bei der extrakorporalen Nierenersatztherapie
US6809076B2 (en) * 2000-03-20 2004-10-26 Abbott Gmbh & Co. Kg Use of anticoagulant agents in the extracorporeal treatment of blood
JP5367202B2 (ja) * 2000-03-20 2013-12-11 アボット ゲーエムベーハー ウント カンパニー カーゲー 血液体外処理における抗凝固剤の使用
DE10102878A1 (de) 2001-01-23 2002-08-01 Haemosys Gmbh Oligo- oder Polyalkylengekoppelte Thrombininhibitoren
DE10162521A1 (de) * 2001-12-19 2003-07-17 Goetz Nowak Verwendung von molekulargewichtserweiterten Substanzen in der Tumortherapie
US7939629B2 (en) 2004-10-19 2011-05-10 Lonza Ag Method for solid phase peptide synthesis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0324712B1 (fr) * 1985-04-11 1993-04-07 Hoechst Aktiengesellschaft Dérivé de l'hirudine
JP2514950B2 (ja) * 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質,その製造法および中間体
FR2628429B1 (fr) * 1988-03-08 1990-12-28 Transgene Sa Variants de l'hirudine, leurs utilisations et les procedes pour les obtenir
AU614121B2 (en) * 1988-05-04 1991-08-22 Novartis Ag Improvements in the production of polypeptides
DE3819079A1 (de) * 1988-06-04 1989-12-07 Hoechst Ag Hirudin-derivate mit verzoegerter wirkung
CA2000887A1 (fr) * 1988-11-01 1990-05-01 Cecilia S.L. Ku Materiaux thromboresistants et methode de production

Also Published As

Publication number Publication date
JP3187044B2 (ja) 2001-07-11
US5663141A (en) 1997-09-02
WO1991008229A1 (fr) 1991-06-13
ES2084149T3 (es) 1996-05-01
CA2067224A1 (fr) 1991-06-02
DE59010205D1 (de) 1996-04-18
ATE135374T1 (de) 1996-03-15
JPH05503092A (ja) 1993-05-27
CA2067224C (fr) 2001-02-13
EP0502962B1 (fr) 1996-03-13
EP0502962A1 (fr) 1992-09-16

Similar Documents

Publication Publication Date Title
BG62068B2 (bg) Хирудинмутеини и техни полиалкиленгликолови конюгати
DE3750056T2 (de) Polypeptid-Mutanten des menschlichen TNF und für diese Mutanten codierende DNS.
US5312736A (en) Anticoagulant analogues of the tissue factor extrinsic pathway inhibitor (EPI) with reduced affinity for heparin
EP0912730B1 (fr) Conjuges de composes peptidiques solubles a agents de liaison de membranes
US5314872A (en) Glucan sulfate, stabilized fibroblast growth factor composition
FI90787C (fi) Menetelmä desulfatohirudiinin valmistamiseksi
JPH08506095A (ja) 改変インシュリン様成長因子
US5977310A (en) Peg-modified HGF
JPH0829097B2 (ja) 線維芽細胞発育因子
BG100420A (bg) Ацилиран инсулин
CA2190752A1 (fr) Facteurs de croissance proches de l'insuline modifies
WO1988003412A1 (fr) Solubilisation de proteines par conjugaison avec la polyproline pour des compositions pharmaceutiques
KR20000016402A (ko) 렙틴(ob단백질)의 프레그먼트
JPH10117786A (ja) 改変された膵臓分泌トリプシン阻害剤およびそれをコードするdna、ならびにそれらの使用
US5783421A (en) DNA encoding novel polypeptide having Factor Xa inhibitory activity
US7163817B2 (en) Clot-specific streptokinase proteins possessing altered plasminogen activation characteristics and a process for their preparation
US5095004A (en) Fluorine containing atrial natriuretic peptides
FR2623400A1 (fr) Facteur d'activation des neutrophiles
US5120715A (en) Method for purifying fibroblast growth factor protein
JPH08511157A (ja) Xaファクター阻害活性を有する新規ポリペプチド
KR20040111639A (ko) 태반성장인자 타입 1 뮤테인의 제조방법 및 이의 사용방법
JP7066067B2 (ja) 組み換えヘモグロビン、その製造方法およびその使用
US5376635A (en) Fluorine containing atrial natriuretic peptides
US6833437B2 (en) Complement receptor type 1 (CR1)-like sequences
CA2001094A1 (fr) Composes chimiques